# Nintedanib

## Ofev 150mg

##### 臨採

| TAH Drug Code      | [OOFE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OOFE)                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Idiopathic Pulmonary Fibrosis (IPF) Indicated for the treatment of idiopathic pulmonary fibrosis (IPF). 2. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Indicated to slow the rate of decline in lung function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). 3. Chronic Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Indicated for the treatment of chronic progressive fibrosing interstitial lung disease (PF-ILD). |
| Dosing             | 150 mg orally every 12 hours (maximum: 300 mg/day)Administer with food. Swallow capsules whole with liquid; do not chew or crush.                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to nintedanib, peanut or soya. Pregnancy & lactation.                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Diarrhoea, nausea, abdominal pain; increased hepatic enzyme. Decreased wt & appetite; epistaxis; vomiting; increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) & γ-glutamyl transferase (GGT).                                                                                                                                                                                                                                                                           |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/nintedanib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                       |

